Abstract:Porcine circovirus type 2 (PCV2) is a globally prevalent infectious pathogen affecting swine, with its capsid protein (Cap) being the sole structural protein critical for vaccine development. Prior research has demonstrated that PCV2 Cap proteins produced in Escherichia coli (E. coli) can form virus-like particles (VLPs) in vitro, and nuclear localization signal peptides (NLS) play a pivotal role in stabilizing PCV2 VLPs. Recently, PCV2d has emerged as an important strain within the PCV2 epidemic. In this study, we systematically optimized the PCV2d Cap protein and successfully produced intact PCV2d VLPs containing NLS using E. coli. The recombinant PCV2d Cap protein was purified through affinity chromatography, yielding 7.5 mg of recombinant protein per 100 ml of bacterial culture. We augmented the conventional buffer system with various substances such as arginine, β-mercaptoethanol, glycerol, polyethylene glycol, and glutathione to promote VLP assembly. The recombinant PCV2d Cap self-assembled into VLPs approximately 20 nm in diameter, featuring uniform distribution and exceptional stability in the optimized buffer. We developed the vaccine and immunized pigs and mice, evaluating the immunogenicity of the PCV2d VLPs vaccine by measuring PCV2-IgG, IL-4, TNF-α, and IFN-γ levels, comparing them to commercial vaccines utilizing truncated PCV2 Cap antigens. The HE staining and immunohistochemical tests confirmed that the PCV2 VLPs vaccine offered robust protection. The results revealed that animals vaccinated with the PCV2d VLPs vaccine exhibited high levels of PCV2 antibodies, with TNF-α and IFN-γ levels rapidly increasing at 14 days post-immunization, which were higher than those observed in commercially available vaccines, particularly in the mouse trial. This could be due to the fact that full-length Cap proteins can assemble into more stable PCV2d VLPs in the assembling buffer. In conclusion, our produced PCV2d VLPs vaccine elicited stronger immune responses in pigs and mice compared to commercial vaccines. The PCV2d VLPs from this study serve as an excellent candidate vaccine antigen, providing insights for PCV2d vaccine research.

Self-assembly of Virus-Like Particles of Porcine Parvovirus

Porcine Parvovirus Capsid Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles with High Immunogenicity in Mice and Guinea Pigs.

The influence of the vegetative nerve system on the maximal conduction velocity in the atrioventricular bundle and in the cardiac ventricles measured by the differential quotient of QRS. Investigations in dogs

Expression and self-assembly of virus-like particles from porcine parvovirus and its application in antibody detection

Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation

A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles

Canine Parvovirus VP2 Protein Expressed in Silkworm Pupae Self-Assembles into Virus-Like Particles with High Immunogenicity

Stability and integrity of self-assembled bovine parvovirus virus‐like particles (BPV‐VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment

Trigger factor assisted self-assembly of canine parvovirus VP2 protein into virus-like particles in Escherichia coli with high immunogenicity

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Exploration on the Expression and Assembly of Virus-Like Particles

Preparation of virus-like particles for porcine circovirus type 2 by YeastFab Assembly

Self-assembly into virus–like particles of the recombinant capsid protein of porcine circovirus type 3 and its application on antibodies detection

Immunogenicity of adenovirus-derived porcine parvovirus-like particles displaying B and T cell epitopes of foot-and-mouth disease

Identification of a Dominant Linear Epitope on the VP2 Capsid Protein of Porcine Parvovirus and Characterization of Two Monoclonal Antibodies with Neutralizing Abilities.

The Pathogenesis of Ossification of the Posterior Longitudinal Ligament

Virus-like Particles vaccine based on co-expression of G5 Porcine rotavirus VP2-VP6-VP7 induces a powerful immune protective response in mice

Erythema‐multiforme‐like contact dermatitis due to capsicum

Optimization and modeling of the homo-polar radial magnetic bearing

Optimized production of full-length PCV2d virus-like particles in Escherichia coli: A cost-effective and high-yield approach for potential vaccine antigen development

Efficient Production of Porcine Circovirus Virus-Like Particles Using the Nonconventional Yeast Kluyveromyces Marxianus